SUCCESSFUL REMISSION OF NON-LUPUS NEAR FULL-HOUSE NEPHROPATHY WITH VOCLOSPORIN: A NOVEL THERAPEUTIC STRATEGY IN A PREGNANCY PLANNING CONTEXT (ISN-WCN 2026) - Mar 20, 2026 - Abstract #WCN26-AB-3327; Pres time: Mar 30, 2026; 05:00 PM - 06:00 PM; Location: Exhibition Hall/Poster Board No. P223; "Evidence for the use of voclosporin in SLE-negative kidney-limited disease is limited, and management can be challenging when pregnancy is planned because of the teratogenicity of mycophenolate mofetil (MMF). voclosporin enabled progressive MMF reduction and safe transition toward preconception while preserving renal stability with low-dose steroids. These findings align with the recent systematic review that defines NLFHN as a distinct entity (Clin J Am Soc Nephrol 2024; 19: 743–754), highlighting voclosporin as a pregnancy-compatible, durable immunosuppressive option for rare glomerular diseases."
Clinical • Cardiovascular • Glomerulonephritis • Hepatitis B • Hepatitis C • Hepatology • Hypertension • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Systemic Lupus Erythematosus
|
|
Chisato Takahashi ∗ 1; Erika Hishida 1; Kazutoshi Ono 2; Yuko Ono 3; Tatemitsu Rai 1; Daisuke Nagata 2
|